Phase III Confirmatory Efficacy and Safety Trial of Remimazolam (CNS7056) Compared With Propofol for Intravenous Anesthesia During Elective Surgery in ASA Class III/IV Patients
Latest Information Update: 17 Jan 2024
Price :
$35 *
At a glance
- Drugs Remimazolam (Primary) ; Propofol; Remifentanil
- Indications General anaesthesia
- Focus Registrational; Therapeutic Use
- Sponsors PAION
- 14 Jan 2024 Primary endpoint has been met. (Percentage (%) of time of Narcotrend Index (NCI) values 60 during maintenance phase of general anesthesia (defined as time between the first skin incision and the completion of the last skin suture))
- 14 Jan 2024 Results comparing the anaesthetic efficacy and the incidence of postinduction hypotension during total intravenous anaesthesia with remimazolam vs. Propofol, published in the Anaesthesia
- 12 May 2021 According to a PAION media release, the marketing approval application (MAA) for Remimazolam for general anesthesia is expected until the end of 2021.